Custom Skin Cancer Shots Stop Tumors From Returning in Landmark Trial

Cambridge, Thursday, 20 August 2026.
Moderna and Merck’s custom mRNA therapy successfully prevented skin cancer recurrence in a landmark final-stage trial, sending Moderna’s stock surging 177% as personalized oncology nears reality.